Business Context and Reporting Period
This Form 8-K Current Report was filed by Skye Bioscience, Inc. on June 14, 2022. The filing primarily addresses an amendment to a previously announced acquisition agreement and a change in the company's independent registered public accounting firm.
Key Financial Metrics
This filing does not contain specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses on corporate governance and transactional updates rather than financial results.
Material Changes
- Amendment to Arrangement Agreement: Skye and Emerald Health Therapeutics, Inc. (EHT) amended their May 11, 2022, Arrangement Agreement. The amendment modifies the post-closing board of directors composition and waives a closing condition requiring a waiver from Emerald Health Biotechnology Espana S.L. regarding change of control payments.
- Change in Certifying Accountant: The Audit Committee dismissed Mayer Hoffman McCann P.C. and engaged Friedman LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, and the quarter ended June 30, 2022.
- Going Concern Note: The prior audit reports by Mayer Hoffman for the years ended December 31, 2021, and 2020, included an explanatory paragraph regarding the company's ability to continue as a going concern.
Guidance, Outlook, and Risks
Outlook and Transaction Status: The acquisition of EHT remains in full force and effect subject to the amendment. Skye intends to file a proxy statement on Schedule 14A containing detailed information about the proposed transaction. Investors are urged to review the management information circular and proxy statement before voting.
Risks and Contingencies: The filing notes that the prior auditor's reports contained a going concern qualification. No disagreements or reportable events were identified between Skye and the former auditor, Mayer Hoffman, regarding accounting principles or audit scope.
Investor Verification Checklist
- Verify the specific changes to the post-closing board of directors outlined in the Amendment to the Arrangement Agreement.
- Review the upcoming Schedule 14A proxy statement for detailed terms of the EHT acquisition and voting procedures.
- Assess the implications of the "going concern" explanatory paragraph found in the 2020 and 2021 audit reports.
- Confirm the transition timeline and scope of work for the new auditor, Friedman LLP.